Ahmad Tarhini· @ATarhiniMDPhD · X·· 1 day agoScore70
Body
#Madrid #ESMO26 | Main findings from INTerpath-001 released: #Intismeran + #pembrolizumab reduced risk of recurrence or death by 42% (HR, 0.58), risk of distant metastasis or death by 38% (HR, 0.62); 24-monRFS rates 82.2% vs 70.0% | Proud to be part of this effort @MoffittNews
157 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Ahmad Tarhini · x.com